US Patent

US9522191 — Modified release formulations containing drug—ion exchange resin complexes

Formulation · Assigned to Tris Pharma Inc · Expires 2027-06-15 · 1y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of making a modified release formulation containing a coated amphetamine-ion exchange resin complex.

USPTO Abstract

An aqueous liquid suspension containing a coated drug-ion exchange resin complex comprising a core composed of an amphetamine complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated amphetamine-ion exchange resin complex is provided. The coated amphetamine-ion exchange resin complex is in admixture with a polymer to form a matrix. Methods of making the coated complex and the liquid suspension are described.

Drugs covered by this patent

Patent Metadata

Patent number
US9522191
Jurisdiction
US
Classification
Formulation
Expires
2027-06-15
Drug substance claim
No
Drug product claim
Yes
Assignee
Tris Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.